Slow-release 5-amino-salicylic acid (Pentasa) for the treatment of active Crohn's disease.
A double-blind, placebo-controlled trial of a slow-release preparation of 5-amino-salicylic acid (Pentasa) has been performed in 40 patients with active Crohn's disease. Over a 6-week period, Pentasa (1.5 g daily) was no different to the dummy tablet in terms of clinical activity (Harvey-Bradshaw Index) or laboratory indicators of inflammation. No serious adverse reactions occurred.
Mahida
Y R
YR
Gastroenterology Unit, Radcliffe Infirmary, Oxford, UK.
Jewell
D P
DP
D000328:Adult; D000636:Aminosalicylic Acids / Q000627:therapeutic use*; D003424:Crohn Disease / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D019804:Mesalamine; D016032:Randomized Controlled Trials as Topic; D013997:Time Factors
D000636:Aminosalicylic Acids; D003692:Delayed-Action Preparations; D019804:Mesalamine